Movement Alert｜EVEREST MED Rises 5.24% in Regular Trading, Drug Registration Application for Domestic Production Transfer of Weishiping Accepted

Market Focus

Sep 18

On September 18, EVEREST MED rose 5.24% in regular trading, trading at HK$27.72/share, with turnover of approximately HK$66.45 million.

The move was driven by the announcement that the company's drug marketing registration application for transferring the production of Weishiping (its marketed product) from overseas to domestic manufacturing has been officially accepted by regulators. This milestone marks a significant step toward localizing production, which could enhance supply chain efficiency and potentially improve cost structure and margin profile for the product going forward.

EVEREST MED is a biopharmaceutical company focused on the development, clinical advancement, manufacturing, and commercialization of innovative drugs and vaccines. The company has built a product pipeline spanning renal diseases, anti-infectives, and autoimmune disorders, with key marketed products including TARPEYO for kidney disease treatment and XERAVA for multi-drug-resistant bacterial infections. Earlier this year, the company also underwent board changes, with Wang Yue appointed as non-executive director in August, bringing experience from康桥 Capital and prior roles at WuXi Biologics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketf.com/news/1199528356"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199528356\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199528356?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 09:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199528356","market":"us","top_or_hot":-1,"title":"Movement Alert｜EVEREST MED Rises 5.24% in Regular Trading, Drug Registration Application for Domestic Production Transfer of Weishiping Accepted","media":"Market Focus","content":"<p><p>On September 18, EVEREST MED rose 5.24% in regular trading, trading at HK$27.72/share, with turnover of approximately HK$66.45 million.</p><p>The move was driven by the announcement that the company's drug marketing registration application for transferring the production of Weishiping (its marketed product) from overseas to domestic manufacturing has been officially accepted by regulators. This milestone marks a significant step toward localizing production, which could enhance supply chain efficiency and potentially improve cost structure and margin profile for the product going forward.</p><p>EVEREST MED is a biopharmaceutical company focused on the development, clinical advancement, manufacturing, and commercialization of innovative drugs and vaccines. The company has built a product pipeline spanning renal diseases, anti-infectives, and autoimmune disorders, with key marketed products including TARPEYO for kidney disease treatment and XERAVA for multi-drug-resistant bacterial infections. Earlier this year, the company also underwent board changes, with Wang Yue appointed as non-executive director in August, bringing experience from康桥 Capital and prior roles at WuXi Biologics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜EVEREST MED Rises 5.24% in Regular Trading, Drug Registration Application for Domestic Production Transfer of Weishiping Accepted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜EVEREST MED Rises 5.24% in Regular Trading, Drug Registration Application for Domestic Production Transfer of Weishiping Accepted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-18 09:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 18, EVEREST MED rose 5.24% in regular trading, trading at HK$27.72/share, with turnover of approximately HK$66.45 million.</p><p>The move was driven by the announcement that the company's drug marketing registration application for transferring the production of Weishiping (its marketed product) from overseas to domestic manufacturing has been officially accepted by regulators. This milestone marks a significant step toward localizing production, which could enhance supply chain efficiency and potentially improve cost structure and margin profile for the product going forward.</p><p>EVEREST MED is a biopharmaceutical company focused on the development, clinical advancement, manufacturing, and commercialization of innovative drugs and vaccines. The company has built a product pipeline spanning renal diseases, anti-infectives, and autoimmune disorders, with key marketed products including TARPEYO for kidney disease treatment and XERAVA for multi-drug-resistant bacterial infections. Earlier this year, the company also underwent board changes, with Wang Yue appointed as non-executive director in August, bringing experience from康桥 Capital and prior roles at WuXi Biologics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1199528356","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199528356","pubTimestamp":1789696424,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 18, EVEREST MED rose 5.24% in regular trading, trading at HK$27.72/share, with turnover of approximately HK$66.45 million.The move was driven by the announcement that the company's drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"异动预警|珠峰医药常规交易大涨5.24%，威氏平国产转让药品注册申请获受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"On September 18, EVEREST MED rose 5.24% in regular trading, trading at HK$27.72/share, with turnover of approximately HK$66.45 million.The move was driven by the announcement that the company's drug marketing registration application for transferring the production of Weishiping (its marketed product) from overseas to domestic manufacturing has been officially accepted by regulators. This milestone marks a significant step toward localizing production, which could enhance supply chain efficiency and potentially improve cost structure and margin profile for the product going forward.EVEREST MED is a biopharmaceutical company focused on the development, clinical advancement, manufacturing, and commercialization of innovative drugs and vaccines. The company has built a product pipeline spanning renal diseases, anti-infectives, and autoimmune disorders, with key marketed products including TARPEYO for kidney disease treatment and XERAVA for multi-drug-resistant bacterial infections. Earlier this year, the company also underwent board changes, with Wang Yue appointed as non-executive director in August, bringing experience from康桥 Capital and prior roles at WuXi Biologics.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}